Drug Landscape ›
Ethinyl estradiol and norelgestromin ›
Regulatory · United States
Marketing authorisations
FDA — authorised 20 November 2001
Application: NDA021180
Marketing authorisation holder: JANSSEN PHARMS
Local brand name: ORTHO EVRA
Indication: FILM, EXTENDED RELEASE — TRANSDERMAL
Status: approved
Read official source →
FDA — authorised 25 February 2021
Application: ANDA213950
Marketing authorisation holder: AMNEAL
Local brand name: ETHINYL ESTRADIOL AND NORELGESTROMIN
Indication: FILM, EXTENDED RELEASE — TRANSDERMAL
Status: approved
Read official source →
FDA — authorised 14 September 2023
Application: ANDA214594
Marketing authorisation holder: ZYDUS PHARMS
Local brand name: ETHINYL ESTRADIOL AND NORELGESTROMIN
Indication: FILM, EXTENDED RELEASE — TRANSDERMAL
Status: approved
Read official source →
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Activities Of Daily Living Impaired — 1 report (10%) Anaemia — 1 report (10%) Emotional Disorder — 1 report (10%) Feeling Abnormal — 1 report (10%) Feeling Drunk — 1 report (10%) Fibromyalgia — 1 report (10%) Gait Disturbance — 1 report (10%) Hunger — 1 report (10%) Impaired Driving Ability — 1 report (10%) Muscle Spasms — 1 report (10%)
Source database →
Ethinyl estradiol and norelgestromin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Ethinyl estradiol and norelgestromin approved in United States?
Yes. FDA authorised it on 20 November 2001; FDA authorised it on 25 February 2021; FDA authorised it on 14 September 2023.
Who is the marketing authorisation holder for Ethinyl estradiol and norelgestromin in United States?
JANSSEN PHARMS holds the US marketing authorisation.